Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAAT3 | P53816 | 1/20 | 0.80 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.80 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.80 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17117415 | 0.96 | PLAAT3 (0.74) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 | |
| SCHEMBL7278495 | 0.96 | PLAAT3 (0.74) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 | |
| SCHEMBL10436226 | 0.95 | PLAAT3 (0.73) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 | |
| SCHEMBL6375210 | 0.92 | KMT2A (0.81) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 | |
| SCHEMBL23417617 | 0.90 | ALDH1A1 (0.77) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23392535 | 0.90 | MAPT (0.77) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29501730 | 0.88 | MEN1 (0.68) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 | |
| SCHEMBL7274811 | 0.87 | ALDH1A1 (0.70) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 | |
| SCHEMBL17117338 | 0.86 | PLAAT3 (0.74) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 | |
| SCHEMBL8828335 | 0.86 | KMT2A (0.64) | PLAAT3PLAAT5PLAAT2PLAAT4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| CN-100432056-C | Tetrahydroisoquinolinylacetamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-12 | — | — | CN | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| CN-1764647-A | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-26 | — | — | CN | disclosed |
| EP-1611104-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | PLAAT3 1638/4885PLAAT5 1146/4885PLAAT2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.